Sign In

Also in this Section

Hepatotoxicity is a phenotype of liver cell injury due to a multitude of causes including drugs, toxins, herbal and dietary supplements, and other agents. The goal of the AASLD Hepatotoxicity SIG is to promote and encourage research, education, and awareness regarding human hepatotoxicity. As such, individuals with any of the following interests and expertise are encouraged to partake in SIG activities.

  • Drug hepatotoxicity
  • Animal and cell culture models of hepatotoxicity
  • Intrinsic and extrinsic mechanisms of hepatocyte death
  • Pharmacogenomics
  • Pharmacoepidemiology
  • Herbal and dietary supplement induced liver injury
  • Regulatory issues involving drugs and HDS products
  • Acute Liver failure
  • Liver transplantation
  • Treatments for acute and chronic hepatotoxicity
  • Liver histopathology
  • Adverse drug events
  • Drug pharmacokinetics and pharmacodynamics
  • Nomenclature of hepatotoxicity

SIG Educational Materials

To view the latest educational materials representing the Hepatotoxicity SIG, such as the revised Drug Induced Liver Injury slide sets, head to AASLD's online educational portal, LiverLearning®.

SIG Leadership

  • Victor J. Navarro, MD, FAASLD
  • Adrian Reuben, MBBS, FRCP, FACG, FAASLD
  • Andrew Stolz, MD
  • Herbert L. Bonkovsky, MD, FAASLD
    Steering Committee
  • Alexander L. Gerbes, MD, FAASLD
    Steering Committee
  • Paul H. Hayashi, MD, MPH
    Steering Committee
  • Joseph Odin, MD, PhD, FAASLD
    Steering Committee
  • Ayako Suzuki, MD, PhD, MSc
    Steering Committee
  • Bette Anne Preston
    Staff Liaison